Rylaze

Chemical Nameasparaginase erwinia chrysanthemi (recombinant)-rywn
Dosage FormInjection (intramuscular; 10 mg/0.5 mL)
Drug ClassEnzymes
SystemBlood
CompanyJazz Pharmaceuticals Inc.
Approval Year2021

Indication

  • A multi-agent chemotherapeutic regimen used for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Prescribing Information2021Jazz Pharmaceuticals Inc., Palo Alto, CA